FDA and Research Peptides: Understanding the Legal Framework

Disclaimer

This is an educational overview of publicly available regulatory information. It is not legal advice. Consult qualified legal counsel for guidance on your specific situation.

---

How the FDA Classifies Peptides

The FDA's jurisdiction over peptides depends primarily on intended use — what the compound is being sold and used for, not its chemical nature alone.

Drug Definition (21 U.S.C. § 321(g))

Under federal law, a substance is a "drug" if it is:

• •Intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease
• •Intended to affect the structure or function of the body

This definition is intentionally broad. The key word is "intended." The FDA looks at how the product is marketed and sold, not just the compound itself.

The Research Use Exemption

Compounds sold explicitly for research purposes — with no claims of human use — occupy a different regulatory space. The FDA has historically focused enforcement on vendors making therapeutic claims rather than on research-use suppliers.

However, this is not a blanket exemption. The research-use-only framing must be genuine:

• •No claims of safety or efficacy for human use on the website, social media, or marketing
• •No targeting of consumers rather than research institutions
• •No sale in forms primarily suited for human administration (pre-filled syringes, dosing guides, etc.)

The Compounding Pharmacy Layer

Separately from research chemicals, compounded peptides fall under different rules:

503A compounding pharmacies prepare patient-specific formulations on prescription. They may use bulk drug substances on the FDA's approved "503A list."

503B outsourcing facilities operate under stricter FDA oversight and can produce larger quantities for distribution to healthcare facilities.

The FDA's 2023–2025 enforcement actions against compounded BPC-157 and other peptides were directed at vendors producing these as 503B products without approved status — a separate issue from research-use sales.

What Researchers Should Know

Safe Harbor Behaviors

• •Document your research purpose. If you are affiliated with an institution, maintain documentation of your research protocol.
• •Buy from research-supply vendors, not from vendors that market as supplement or therapeutic providers.
• •Keep records of all purchases, including the vendor's COA and your stated purpose.

Risk Factors

• •Vendors with wellness, health improvement, or anti-aging marketing language carry higher regulatory risk
• •Vendors marketing to athletes or fitness communities are under increased scrutiny
• •Purchasing quantities inconsistent with research use can attract attention

The PepAssure Approach

PepAssure's vendor scoring specifically flags vendors who make therapeutic or health claims in their marketing. Our Vendor Transparency pillar includes an assessment of how vendors present their products.

Vendors with high PVS scores are generally those operating with clear research-use framing, strong COA documentation, and legitimate business practices — the factors that correlate with reduced regulatory risk.

---

*Regulatory status can change rapidly. This overview reflects the environment as of April 2026.*